7-Hydroxymitragynine Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Kratom-derived indole alkaloid; opioid receptor ligand compound Reference needs_revision Best effort · source review pending

Also known as: 7-HMG, 7-OH, 7-OH-MIT, 7-OHMZ, 7-hydroxy-mitragynine, Mitragynine hydroxyindolenine

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

7-Hydroxymitragynine is a stereochemically defined alkaloid with molecular formula C23H30N2O5 and molecular weight approximately 414.5 g/mol. It occurs naturally as a minor constituent of Mitragyna speciosa and is also formed as an oxidative metabolite of mitragynine in biological systems. Pharmacology studies describe activity at opioid receptors, with predominant mu-opioid receptor agonism and substantially greater potency than mitragynine in several experimental assays. No FDA-approved drug containing 7-hydroxymitragynine has been identified.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Human pharmacokinetic assessment after oral mitragynine administration reported a 7-hydroxymitragynine apparent half-life of approximately 1.7-4.7 hours; a validated human half-life after direct administration of isolated 7-hydroxymitragynine has not been established. In male Sprague-Dawley rats, direct oral and intravenous pharmacokinetic studies have been reported, but the cited abstract does not provide a single elimination half-life value.

Onset

Not established as a reliable human clinical parameter. In mice, antinociceptive activity was assessed after oral or subcutaneous administration in preclinical time-course studies.

Administration Routes (Research)

oralsubcutaneousintravenous

Reported Research Effects

Mu-opioid receptor agonist activity in receptor-binding and functional assays
Competitive antagonist activity at kappa- and delta-opioid receptors reported in a human-receptor signaling study
Antinociceptive effects in mouse tail-flick and hot-plate models after oral and subcutaneous administration
Respiratory depression, rewarding effects, physical dependence, and withdrawal-related effects reported in preclinical or toxicological assessments

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

In the original mouse antinociception study, subcutaneous doses of 2.5-10 mg/kg and oral doses of 5-10 mg/kg were evaluated. A later rat pharmacokinetic study evaluated direct oral administration at 5 mg/kg and intravenous administration; the study reported rapid absorption, low oral bioavailability of approximately 2.7%, oral Tmax approximately 0.3 hours, intravenous clearance approximately 4.0 L/h/kg, and volume of distribution approximately 2.7 L/kg. These are animal-study reference parameters and are not human dosing recommendations.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN: 174418-82-7; PubChem CID: 44301524; UNII: 2T3TWA75R0; ChEBI: CHEBI:180536; ChEMBL: CHEMBL61630; EPA DSSTox: DTXSID20903988; InChIKey: RYENLSMHLCNXJT-CYXFISRXSA-N; molecular formula: C23H30N2O5; molecular weight: 414.5 g/mol; IUPAC name: methyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate

Source-Backed Observations

Natural kratom leaf generally contains 7-hydroxymitragynine at trace or minor levels, substantially below the concentrations reported for enhanced or concentrated preparations. Human evidence is limited and largely concerns 7-hydroxymitragynine measured as a metabolite after mitragynine or kratom administration rather than direct administration of isolated compound. FDA states that 7-hydroxymitragynine is not approved for medical use.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa
https://pubmed.ncbi.nlm.nih.gov/14969718/ (accessed 2026-09-20)

Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
https://pubmed.ncbi.nlm.nih.gov/27192616/ (accessed 2026-09-20)

In Vitro and In Vivo Pharmacokinetic Characterization of 7-Hydroxymitragynine, an Active Metabolite of Mitragynine, in Sprague-Dawley Rats
https://pubmed.ncbi.nlm.nih.gov/40119246/ (accessed 2026-09-20)

7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat
https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf (accessed 2026-09-20)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.